Advances in the pharmacotherapy of hereditary angioedema

Laura M. Cotiguala; Kelli L. Coover; Againdra K. Bewtra; Mark A. Malesker

Advances in the pharmacotherapy of hereditary angioedema

Laura M. Cotiguala, Kelli L. Coover, Againdra K. Bewtra, Mark A. Malesker

Department of Pharmacy Practice

Research output: Contribution to specialist publication › Article

Abstract

Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.

Original language	English (US)
Pages	HS17-HS21
Volume	40
No	10
Specialist publication	U.S. Pharmacist
State	Published - Oct 16 2015

All Science Journal Classification (ASJC) codes

Pharmacy
Pharmacology
Pharmaceutical Science

Access to Document

Fingerprint Dive into the research topics of 'Advances in the pharmacotherapy of hereditary angioedema'. Together they form a unique fingerprint.

Cite this

Cotiguala, L. M., Coover, K. L., Bewtra, A. K., & Malesker, M. A. (2015). Advances in the pharmacotherapy of hereditary angioedema. U.S. Pharmacist, 40(10), HS17-HS21.

@misc{797b8431102a42a18fba4421a14523aa,

title = "Advances in the pharmacotherapy of hereditary angioedema",

abstract = "Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists{\textquoteright} understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.",

author = "Cotiguala, {Laura M.} and Coover, {Kelli L.} and Bewtra, {Againdra K.} and Malesker, {Mark A.}",

year = "2015",

month = oct,

day = "16",

language = "English (US)",

volume = "40",

pages = "HS17--HS21",

journal = "U.S. Pharmacist",

issn = "0148-4818",

publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Advances in the pharmacotherapy of hereditary angioedema

AU - Cotiguala, Laura M.

AU - Coover, Kelli L.

AU - Bewtra, Againdra K.

AU - Malesker, Mark A.

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.

AB - Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.

UR - http://www.scopus.com/inward/record.url?scp=84944453594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944453594&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84944453594

VL - 40

SP - HS17-HS21

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -